309 related articles for article (PubMed ID: 36230467)
1. Proteasome Inhibitors and Their Potential Applicability in Osteosarcoma Treatment.
Van Stiphout CM; Luu AK; Viloria-Petit AM
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230467
[TBL] [Abstract][Full Text] [Related]
2. Proteasome Inhibitors for the Treatment of Multiple Myeloma.
Ito S
Cancers (Basel); 2020 Jan; 12(2):. PubMed ID: 31979059
[TBL] [Abstract][Full Text] [Related]
3. The Proteasome Inhibitor Ixazomib Inhibits the Formation and Growth of Pulmonary and Abdominal Osteosarcoma Metastases in Mice.
Harris MA; Miles MA; Shekhar TM; Cerra C; Georgy SR; Ryan SD; Cannon CM; Hawkins CJ
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32403415
[TBL] [Abstract][Full Text] [Related]
4. Soluble and Cell-Cell-Mediated Drivers of Proteasome Inhibitor Resistance in Multiple Myeloma.
Farrell ML; Reagan MR
Front Endocrinol (Lausanne); 2018; 9():218. PubMed ID: 29765356
[TBL] [Abstract][Full Text] [Related]
5. Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.
Leleu X; Martin TG; Einsele H; Lyons RM; Durie BGM; Iskander KS; Ailawadhi S
Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):9-22. PubMed ID: 30287200
[TBL] [Abstract][Full Text] [Related]
6. Safety of proteasome inhibitors for treatment of multiple myeloma.
Schlafer D; Shah KS; Panjic EH; Lonial S
Expert Opin Drug Saf; 2017 Feb; 16(2):167-183. PubMed ID: 27841029
[TBL] [Abstract][Full Text] [Related]
7. The power of proteasome inhibition in multiple myeloma.
Guerrero-Garcia TA; Gandolfi S; Laubach JP; Hideshima T; Chauhan D; Mitsiades C; Anderson KC; Richardson PG
Expert Rev Proteomics; 2018 Dec; 15(12):1033-1052. PubMed ID: 30427223
[TBL] [Abstract][Full Text] [Related]
8. Old and new generation proteasome inhibitors in multiple myeloma.
Montefusco V; Mussetti A; Salas MQ; Martinelli G; Cerchione C
Panminerva Med; 2020 Dec; 62(4):193-206. PubMed ID: 32957744
[TBL] [Abstract][Full Text] [Related]
9. Spotlight on ixazomib: potential in the treatment of multiple myeloma.
Muz B; Ghazarian RN; Ou M; Luderer MJ; Kusdono HD; Azab AK
Drug Des Devel Ther; 2016; 10():217-26. PubMed ID: 26811670
[TBL] [Abstract][Full Text] [Related]
10. Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma.
Kubiczkova L; Pour L; Sedlarikova L; Hajek R; Sevcikova S
J Cell Mol Med; 2014 Jun; 18(6):947-61. PubMed ID: 24712303
[TBL] [Abstract][Full Text] [Related]
11. Comparative mechanisms of action of proteasome inhibitors.
Wang M
Oncology (Williston Park); 2011 Nov; 25 Suppl 2():19-24. PubMed ID: 25188479
[TBL] [Abstract][Full Text] [Related]
12. [Role of novel proteasome inhibitors in the treatment of relapsed/refractory multiple myeloma].
Ri M
Rinsho Ketsueki; 2018; 59(10):2162-2168. PubMed ID: 30305522
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling.
Accardi F; Toscani D; Bolzoni M; Dalla Palma B; Aversa F; Giuliani N
Biomed Res Int; 2015; 2015():172458. PubMed ID: 26579531
[TBL] [Abstract][Full Text] [Related]
14. Pre-clinical evaluation of proteasome inhibitors for canine and human osteosarcoma.
Patatsos K; Shekhar TM; Hawkins CJ
Vet Comp Oncol; 2018 Dec; 16(4):544-553. PubMed ID: 29998615
[TBL] [Abstract][Full Text] [Related]
15. [Proteasome inhibitors in first-line treatment of transplant-ineligible multiple myeloma patients].
Kuroda J; Shimura Y
Rinsho Ketsueki; 2017; 58(8):999-1005. PubMed ID: 28883286
[TBL] [Abstract][Full Text] [Related]
16. Proteasome inhibitors for the treatment of multiple myeloma.
Scalzulli E; Grammatico S; Vozella F; Petrucci MT
Expert Opin Pharmacother; 2018 Mar; 19(4):375-386. PubMed ID: 29478351
[TBL] [Abstract][Full Text] [Related]
17. Non-lethal proteasome inhibition activates pro-tumorigenic pathways in multiple myeloma cells.
Skorda A; Sklirou AD; Sakellaropoulos T; Gianniou DD; Kastritis E; Terpos E; Tsitsilonis OE; Florea BI; Overkleeft HS; Dimopoulos MA; Alexopoulos LG; Trougakos IP
J Cell Mol Med; 2019 Dec; 23(12):8010-8018. PubMed ID: 31568628
[TBL] [Abstract][Full Text] [Related]
18. [The proteasome - structural aspects and inhibitors: a second life for a validated drug target].
Reboud-Ravaux M
Biol Aujourdhui; 2021; 215(1-2):1-23. PubMed ID: 34397372
[TBL] [Abstract][Full Text] [Related]
19. New proteasome inhibitors in myeloma.
Lawasut P; Chauhan D; Laubach J; Hayes C; Fabre C; Maglio M; Mitsiades C; Hideshima T; Anderson KC; Richardson PG
Curr Hematol Malig Rep; 2012 Dec; 7(4):258-66. PubMed ID: 23065395
[TBL] [Abstract][Full Text] [Related]
20. From bortezomib to other inhibitors of the proteasome and beyond.
Buac D; Shen M; Schmitt S; Kona FR; Deshmukh R; Zhang Z; Neslund-Dudas C; Mitra B; Dou QP
Curr Pharm Des; 2013; 19(22):4025-38. PubMed ID: 23181572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
